Blonanserin is primarily used for the treatment of schizophrenia, particularly atypical psychosis. It is a second-generation atypical antipsychotic agent that acts as a selective antagonist of dopamine D2/D3 and serotonin 5-HT2A receptors, with minimal affinity for D1, α1-adrenergic, H1 histamine, and M1 muscarinic receptors. Due to its high receptor selectivity and favorable safety profile, it is associated with a lower incidence of extrapyramidal side effects (EPS) compared to typical antipsychotics like haloperidol, and a reduced risk of orthostatic hypotension compared to risperidone. It demonstrates efficacy in improving both positive and negative symptoms of schizophrenia, with clinical studies showing comparable or superior tolerability and effectiveness relative to haloperidol and risperidone.